drugset / Trial / NCT04934774
Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances
Phase 1
Unknown
20 enrolled
iCell Gene Therapeutics
Peking University Shenzhen Hospital · collabiCAR Bio Therapeutics Ltd. · collab
NaSequentialOpen-labelTreatment
Summary
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of non-gene edited anti-CD7 CAR (also called anti-CD7 CAR) T cells in patients with relapsed and/or refractory T cell lymphoma or leukemia
Timeline
- Start
- 2020-12-01
- Primary completion
- 2023-06-01
- Completion
- 2023-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD7 CAR-T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CD7 CAR-T cells | Cell therapy | 5e+06 cells/kg | Intravenous |